Gold(I) ion and the phosphine ligand are necessary for the anti- Toxoplasma gondii activity of auranofin
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.02968-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von C I Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of California at Irvine, Irvine, California, USA. Hauptthemen laut MEDLINE: Toxoplasma, Arthritis, Rheumatoid, Toxoplasmosis, Phosphines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health, Robert Wood Johnson Foundation.
Abstract (Originalsprache)
Auranofin, an FDA-approved drug for rheumatoid arthritis, has emerged as a promising antiparasitic medication in recent years. The gold(I) ion in auranofin is postulated to be responsible for its antiparasitic activity. Notably , aurothiomalate and aurothioglucose also contain gold(I), and, like auranofin, they were previously used to treat rheumatoid arthritis. Whether they have antiparasitic activity remains to be elucidated. Herein, we demonstrated that auranofin and similar derivatives, but not aurothiomalate and aurothioglucose, inhibited the growth of Toxoplasma gondii in vitro . We found that auranofin affected the T. gondii biological cycle (lytic cycle) by inhibiting T. gondii’s invasion and triggering its egress from the host cell. However, auranofin could not prevent parasite replication once T. gondii resided within the host. Auranofin treatment induced apoptosis in T. gondii parasites , as demonstrated by its reduced size and elevated phosphatidylserine externalization (PS). Notably, the gold from auranofin enters the cytoplasm of T. gondii, as demonstrated by scanning transmission electron microscopy-energy dispersive X-ray spectroscopy (STEM-EDS) and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). IMPORTANCE Toxoplasmosis, caused by Toxoplasma gondii , is a devastating disease affecting the brain and the eyes, frequently affecting immunocompromised individuals. Approximately 60 million people in the United States are already infected with T. gondii , representing a population at-risk of developing toxoplasmosis. Recent advances in treating cancer, autoimmune diseases, and organ transplants have contributed to this at-risk population's exponential growth. Paradoxically, treatments for toxoplasmosis have remained the same for more than 60 years, relying on medications well-known for their bone marrow toxicity and allergic reactions. Discovering new therapies is a priority, and repurposing FDA-approved drugs is an alternative approach to speed up drug discovery. Herein, we report the effect of auranofin, an FDA-approved drug, on the biological cycle of T. gondii and how both the phosphine ligand and the gold molecule determine the anti-parasitic activity of auranofin and other gold compounds. Our studies would contribute to the pipeline of candidate anti- T. gondii agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, University of California at Irvine, Irvine, California, USA.
- Department of Microbiology and Molecular Genetics, University of California at Irvine, Irvine, California, USA.
- School of Biological Sciences; University of California at Irvine, Irvine, California, USA.
- Irvine Materials Research Institute; University of California at Irvine, Irvine, California, USA.
- Department of Medicine, Occupational and Environmental Medicine, University of California at Irvine, Irvine, California, USA.
- Department of Medicinal Chemistry, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
ORCID-Profile: R M Andrade
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
- Robert Wood Johnson Foundation
Zitieren
APA
Ma, C. I., Tirtorahardjo, J. A., Schweizer, S. S., Zhang, J., Fang, Z., Xing, L., Xu, M., Herman, D. A., Kleinman, M. T., McCullough, B. S., Barrios, A. M., & Andrade, R. M. (2024). Gold(I) ion and the phosphine ligand are necessary for the anti- Toxoplasma gondii activity of auranofin. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02968-23
Vancouver
Ma CI, Tirtorahardjo JA, Schweizer SS, Zhang J, Fang Z, Xing L, et al. Gold(I) ion and the phosphine ligand are necessary for the anti- Toxoplasma gondii activity of auranofin. Microbiology Spectrum. 2024. doi:10.1128/spectrum.02968-23
BibTeX
@article{Ma2024,
author = {Ma, C I and Tirtorahardjo, J A and Schweizer, S S and Zhang, J and Fang, Z and Xing, L and Xu, M and Herman, D A and Kleinman, M T and McCullough, B S and Barrios, A M and Andrade, R M},
title = {Gold(I) ion and the phosphine ligand are necessary for the anti- Toxoplasma gondii activity of auranofin},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.02968-23}
}
EUVIMED